Tackle three tenets in tandem to cultivate digital trust — and a competitive edge

EY Woman at coffee shop on laptop

An award-winning culture

We’ve been recognized by Great Place to Work®, LinkedIn and Universum as an exceptional workplace.

EY - Best Workplaces
EY - Best Workplaces in Professional Services
EY - Best Workplaces for Women
EY - Best Workplaces in Ontario
EY - LinkedIn - Top companies
EY - Universum - Most Attractive Employers

2021 corporate responsibility report

See how we’re building a better working world.

Read report

Featured press releases

Nearly half of Canadians say they plan to buy an electric vehicle as cost concerns fade

38% worry about upfront EV pricing, down from 66% in 2021

22 Jun. 2022 Toronto CA

EY recognizes 17 Atlantic businesses in annual entrepreneur program

Entrepreneurs are digitalizing operations to unlock new value for stakeholders

30 May 2022 Halifax CA

More press releases

EY recognizes 27 Prairies businesses in annual entrepreneur program

Entrepreneurs are building the social and economic fabric of the community

26 May 2022

EY recognizes 24 Pacific businesses in annual entrepreneur program

Entrepreneurs strengthening market position post-pandemic

18 May 2022

EY recognizes 23 Québec businesses in annual entrepreneur program

Entrepreneurs redefining the path to success

17 May 2022

WEOY winner 2022 Argentina Gaston Taratuta on stage

EY World Entrepreneur Of The Year™ 2022

Congratulations to EY World Entrepreneur Of The YearTM 2022, Gaston Taratuta of Aleph in Argentina, and EY Social Entrepreneurship Award winner Stella McCartney.

Find out more

Strategy, transactions and transformation

EY can help you realize your ambitions by offering a radically different approach to connecting strategy, transactions, transformation and technology, where design and delivery inform each other at every step.

Explore

Sustainability

EY is committed to making business work for sustainability and sustainability work for business. We can help you create new value from the innovation opportunity of our lifetime.

Explore

Case Study
The better the question The better the answer The better the world works
Case Study

Bayer’s journey to becoming a preferred partner in clinical trials

The pharmaceutical company sought to improve site relationships and drive industry-leading practices.

Case Study
The better the question The better the answer The better the world works
Case Study

How did Bayer become a preferred partner for clinical trials?

Leading pharma company Bayer sought to improve site relationships and drive leading practices.

Local Contact : Raj Saxena, EY Canada Partner, National Life Sciences Practice Leader

After encountering challenges in its clinical trial site management processes and timeline, Bayer conducted a comprehensive review of its site management processes and identified site payment improvements as a focus area. When it comes to site-sponsor relationships, payment management has a significant impact on both the partnership and site activity. Managing complex invoicing processes, following up with sponsors on payment statuses or reconciling payments all take time that could be better spent recruiting patients and conducting research.

In the US, Bayer identified opportunities to enhance payment efficiency, timeliness and accuracy to strengthen its site relationships, enable better-informed decisions and contribute to its goal of becoming a preferred clinical trial site partner. Downstream, these site payment improvements targeted reducing administrative burdens for both Bayer and its clinical partners and improving study closeout.

The company sought help from Ernst & Young LLP (EY US) to transform its clinical site invoicing and payment approach. Bayer focused on addressing three key pain points:

  1. Reliance on manual processes: Bayer’s current state process required manual — and often duplicative — effort to cross-reference site activities against the original contract and budget.
  2. Lack of transparency: Tracking and reporting invoice and payment statuses across multiple data sources caused additional difficulties in achieving payment accuracy and for the clinical sites to quickly reconcile their reimbursements.
  3. Inconsistency in timely payments: Overall, the additional time and effort required for the process left Bayer at risk for delayed payment statements. Further, payment statements themselves were often difficult for the clinical sites to understand.
ey-chapter-1
Case Study
The better the question The better the answer The better the world works
Case Study

Site payment solution streamlines processes and lowers costs

Bayer Healthcare US and EY US deployed the Automated Site Payments and Invoice Resolution program.

After an in‑depth examination of Bayer’s processes and an understanding of future state goals, the Automated Site Payments and Invoice Resolution (ASPIREs) program addressed Bayer’s challenges on four fronts:

  1. Process efficiency: reduce inefficiencies in Bayer site management and, ultimately, for sites and clinicians in parallel
  2. Site satisfaction: enable timely, accurate payments and reduce payment disputes to improve site satisfaction
  3. Transparency: provide real-time reporting on invoicing and site payment statuses with increased transparency
  4. Resource allocation: utilize third-party services and payment analytics to drive efficiencies through eliminating manual tasks and duplicative efforts
ey-chapter-2
Case Study
The better the question The better the answer The better the world works
Case Study

Innovation that improves how patients experience clinical trials

Clinical trial sites experience heightened confidence about working with pharma.

ASPIREs enabled Bayer and its clinical trial site partners to experience an expedient, streamlined clinical trial process. Among improvements in the US, Bayer’s average cycle time for payment to site dropped from 75 days to fewer than 35 days. The company was able to easily make its payment dates and increase the satisfaction of physicians and clinical trial sites. By reducing the administrative burden of payment processes, Bayer was able to continue focusing on driving innovation.

The results highlight significant ROI in the US, with global data expected soon:

75%+

reduction in number of payment-related questions and disputes

55%+

reduction in cycle time for payment to site (payment processing)

80%+

reduction in number of templates required for reporting and forecasting

90%+

reduction in monthly hours spent supporting payment processes per study, per resource

As Mark Ryan, Bayer’s US Head of Site Management, said, “Partners and patients can count on best practices being used in Bayer-sponsored studies.” Automation has driven clear efficiencies and cost savings for Bayer. Ultimately, it is a differentiator in the marketplace that improves Bayer’s customer service. As Bayer continues to act on its commitment to become a preferred partner, it enables clinical trial sites to focus on what’s most important: driving access to cutting-edge therapies and revitalizing patient care.

Contributor: Salman Shah, Principal, Consulting, Business Design, Health Research & Development (R&D) Lead, Ernst & Young LLP

group-of-doctors-talking-chapter-3

Direct to your inbox

Stay up to date with our Editor's Picks newsletter. 

Subscribe

Next

Insights